Antisense Oligonucleotides and Their Anticancer Activities

  • D. Fabbro
  • M. Müller
  • T. Geiger
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 131)


Available cancer therapies still have only limited success against most solid cancer types and inevitably result in the development of multidrug-resistant tumors. There is an urgent need for therapeutic alternatives aiming at compounds with better tolerability at efficacious doses that are directed at defined, disease-relevant molecular targets. The progress made in understanding the molecular basis of mammalian cell transformation has led to the unifying concept of growth regulation and its disorders in cancer cells. It is now well recognized that many products of “cancer genes” encode for proteins that regulate normal mitogenesis and apoptosis. Taken together, these indicate that the carcinogenic process may be viewed as a progressive disorder of signal transduction (Croce 1987;Alitalo et al. 1988;Bos 1989;Bishop 1991;Rabbitts 1994;Weinberg 1994). In fact, many of the genes that are mutated or lost in cancer cells, including both the oncogenes and tumor suppressers, encode proteins that are crucial regulators for both intra-and intercellular signal transduction (Croce 1987;Alitalo et al. 1988;Bos 1989;Bishop 1991;Rabbitts 1994;Weinberg 1994). This conceptual framework has provided a basis for the development of novel anticancer strategies and therapeutic modalities aimed at inhibiting cancer growth either by blocking mitogenic signal transduction or specifically inducing apoptosis of cancer cells. Although the various approaches have not been clinically validated, these strategies are likely to identify compounds with fewer side effects compared to standard chemotherapeutic agents.


Nude Mouse Antitumor Activity Antisense Oligonucleotide Dextran Sulfate Mitogenic Signal Transduction 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Ahmad S, Glazer RI (1993) Expression of the antisense cDNA for protein kinase Ca attenuates resistance in doxorubicin-resistant MCF-7 breast carcinoma cells. Mol Pharmacol 43:858PubMedGoogle Scholar
  2. Ahmad S, Mineta T, Martuza RL, Glazer RI (1994) Antisense expression of protein kinase Ca inhibits the growth and tumorigenicity of human glioblastoma cells. Neurosurgery 35:904PubMedCrossRefGoogle Scholar
  3. Alitalo K, Schwab M (1988) Oncogene amplification in tumor cells. Adv Cancer Res 46:235Google Scholar
  4. Altmann KH, Dean NM, Fabbro D, Freier SM, Geiger T, Häner R, Hüsken D, Martin P, Monia BP, Müller M, Natt F, Nicklin P, Phillips J, Pieles U, Sasmor H, Moser HE (1996) Second generation of antisense oligonucleotides: From nuclease resistance to biological efficacy in animals. Chimia 50:168–176Google Scholar
  5. Ambrose D, Resnicoff M, Coppola D, Sell C, Miura M, Jameson S, Baserga R, Rubin R (1994) Growth regulation of human gioblastoma T98G cells by insulin-like growth factor-1 and its receptor. J Cell Physiol 159:92PubMedCrossRefGoogle Scholar
  6. Aoki K, Yoshida T, Sugimura T, Terada M (1995) Liposome-mediated in vivo gene transfer of antisense K-ras construct inhibits pancreatic tumor dissemination in the murine pertoneal cavity. Cancer Res 55:3810PubMedGoogle Scholar
  7. Autieri MV, Yue TL, Ferstein GZ, Ohlstein E (1995) Antisense oligonucleotides to the p65 subunit of NF-kB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 213:827CrossRefGoogle Scholar
  8. Barcellini-Couget S, Pradines-Figuere A, Roux P, Dani C, Iilhaud G (1993) The regulation of growth hormone of lipoprotein lipase gene expression is mediated by c-fos protooncogene. Endocrinology 132:53PubMedCrossRefGoogle Scholar
  9. Baserga R, Reiss K, Alder H, Pietrozkowski Z, Surmacz E (1992) Inhibition of cell cycle progression by antisense oligodeoxynucleotides. Ann NY Acad Sci 660:64PubMedCrossRefGoogle Scholar
  10. Bayever E, Iversen P (1994) Oligonucleotides in the treatment of leukemia. Hematol Oncol 12:9PubMedCrossRefGoogle Scholar
  11. Becker D, Meier CB, Herlyn M (1989) Proliferation of human malignant melanomas is inhibited by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. EMBO J 8:3685PubMedGoogle Scholar
  12. Becker D, Lee PL, Rodeck U, Herlyn M (1992) Inhibition of the fibroblast growth factor receptor 1 gene in human melanocytes and malignant melanomas leads to inhibition of proliferation and signs indicative of differentiation. Oncogene 7:2303PubMedGoogle Scholar
  13. Behl C, Bogdahn U, Winkler J, Apfel R, Brysch WI, Schlingensiepen KH (1993) Antiinduction of platelet-derived growth factor A-chain mRNA expression in a human malignant melanoma cell line and growth-inhibitory effects of PDGF A-chain mRNA-specific antisense molecules. Biochem Biophys Res Commun 193:744PubMedCrossRefGoogle Scholar
  14. Behrend E I, Craig AM, Wilson SM, Denhardt DT, Chambers AF (1994) Reduced malignancy of ras-transformed NIH 3T3 cells expressing antisense osteopontin RNA. Cancer Res 54:832PubMedGoogle Scholar
  15. Bello-Rehss E, Ernest S (1994) Expression and function of P-glycoprotein in human mesangial cells. Am J Physiol 267:C1351Google Scholar
  16. Bennett MR, Anglin S, McEwan FR, Jagoe R, Newby AC, Evan GI (1994) Inhibition of vascular smooth muscle cell proliferation in vitro and in vivo by c-myc antisense oligodeoxynucleotides. J Clin Invest 93:820PubMedCrossRefGoogle Scholar
  17. Bergmann R, Funatomi H, Yokoyama M, Berger HG, Korc M (1995) Insulin-line growth factor-1 overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 55:2007PubMedGoogle Scholar
  18. Bishop JM (1991) Molecular themes in oncogenesis. Cell 64:235PubMedCrossRefGoogle Scholar
  19. Blenis J (1993) Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A 90:5889PubMedCrossRefGoogle Scholar
  20. Bos JL (1989) Ras oncogene in human cancer: a review. Cancer Res 49:4682PubMedGoogle Scholar
  21. Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen A, Herrera CJ, Hu SS, Kramer TB (1995) The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism. Proc Natl Acad Sci U S A 92:4051PubMedCrossRefGoogle Scholar
  22. Busch RK, Perlaky L, Valdez BC, Henning D, Busch H (1994) Apoptosis in human tumor cells following treatment with p120 antisense oligodeoxynucleotide ISIS 3466. Cancer Lett 86:151PubMedCrossRefGoogle Scholar
  23. Calabretta B, Sims RB, Valtieri M, Caracciolo D, Szczylik C, Venturelli D, Ratajczak M, Beran M, Gewirtz AM (1991) Normal and leukemic hematopoietic cells manifest differential sensitivity to inhibitory effects of c-myb antisense oligonucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad Sci U S A 88:2351PubMedCrossRefGoogle Scholar
  24. Calabretta B, Skorski T, Szczylik C, Zon G (1993) Prospects for gene-directed therapy with antisense oligodeoxynucleotides. Cancer Treat Rev 19:169PubMedCrossRefGoogle Scholar
  25. Calara F, Ameli S, Hultgardh-Nilsson J (1996) Autocrine induction of DNA synthesis by mechanical injury of cultured smooth muscle cells. Potential role of FGF and PDGF. Arterioscler Thromb Vasc Biol 16:187PubMedCrossRefGoogle Scholar
  26. Cantley LC, Auger KR, Carpenter C, Duckworth B, Graziani A, Kapeller R, Soltoff S (1991) Oncogenes and signal transduction. Cell 64:281PubMedCrossRefGoogle Scholar
  27. Carter G, Lemoine NR (1993) Antisense technology for cancer therapy: does it make sense? Br J Cancer 67:869PubMedCrossRefGoogle Scholar
  28. Chakrabarty S, Rajagopal S, Huang S (1995) Expression of antisense epidermal growth factor receptor RNA down modulates the malignant behaviour of human colon cancer cells. Clin Exp Metastasis 13:191PubMedCrossRefGoogle Scholar
  29. Cho-Chung Y-S (1993) Antisense oligonucleotides for the treatment of cancer. Curr Opin Ther Pat 3:1737CrossRefGoogle Scholar
  30. Cho-Chung Y-S, Clair T (1993) The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy and cancer and other cellular dysfunctional-related disease. Pharmacol Ther 60:265PubMedCrossRefGoogle Scholar
  31. Ciardiello F, Tortora G, Bianco C, Selvam MP, Basolo F, Fontanini G, Pacifico F, Normanno N, Brandt R, Persico, MG (1994) Inhibition of CRIPTO expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogene 9:291PubMedGoogle Scholar
  32. Collins S, Groudine M (1982) Amplification of endogenous myc-related DNA sequences in a human myeloid leukemia cell line. Nature 299:679CrossRefGoogle Scholar
  33. Colomer R, Lupu R, Bacus SS, Gelman EP (1994) erbB-2 antisense oligonucleotides inhibit the proliferation of breast carcinoma cells with erbB-2 oncogene amplification. Br J Cancer 70:819PubMedCrossRefGoogle Scholar
  34. Colotta F, Polentarutti N, Sironi M, Mantovani A (1992) Expression and involvement of c-fos and c-jun protooncogenes in programmed cell death induced by growth factor deprivation in lymphoid cell lines. J Biol Chem 267:18278PubMedGoogle Scholar
  35. Cotter FE, Johnson P, Hall P, Pocock C, As Mandi NA, Cowell JK, Morgan G (1994) Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene, 9:3049PubMedGoogle Scholar
  36. Croce CM (1987) Role of chromosome translocations in human neoplasia. Cell 49:155 Crooke ST (1992) Therapeutic application of oligonucleotides. Annu Rev Pharmacol Toxicol 32:329Google Scholar
  37. Dean NM, McKay R, Condon TP, Bennett CF (1994) Inhibition of protein kinase C-a expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 269:1Google Scholar
  38. Dean NM, McKay R, Miraglia L, Howard R, Meister L, Ziel R, Geiger T, Müller M, Fabbro D (1996) Inhibition of growth of human tumor cell lines in nude mice by an antisense oligonucleotide inhibitor of PKC-a expression. Cancer Res 56: 3499PubMedGoogle Scholar
  39. Degols G, Leonetti JP, Mechti N, Lebleu B (1991) Antiproliferative effects of antisense oligonucleotides directed to the RNA of c-myc oncogene. Nucleic Acids Res 19:945PubMedCrossRefGoogle Scholar
  40. Dietel M (1993) Meeting report: second international symposium on cytostatic drug resistance. Cancer Res 53:2683PubMedGoogle Scholar
  41. Ebbecke M, Unterberg C, Buchwald A, Stohr S, Wiegand V (1992) Antiproliferative effects of a c-myc antisense oligonucleotide on human arterial smooth muscle cells. Basic Res Cardiol 87:585PubMedCrossRefGoogle Scholar
  42. Ensoli JB, Markham P, Kao V, Barillari G, Fiorelli V, Gendelman R, Raffeld M, Zon G, Galo RC (1994) Block of AIDS-Kaposi’s sarcoma cell growth, angiogenesis and lesion formation in nude mice by antisense oligonucleotide targeting basic fibroblast growth factor. A novel strategy for the therapy of Kaposi sarcoma. J Clin Invest 94:1736PubMedCrossRefGoogle Scholar
  43. Fakhrai H, Dorigo O, Shawler DL, Lin HN, Mercola D, Black KL, Royston I, Sobol RE (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci U S A 93:2902CrossRefGoogle Scholar
  44. Fidler IJ (1995) Invasion and metastasis. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds) Clinical oncology. Churchill Livingstone, Edinburgh, pp 4576Google Scholar
  45. Fitzpatrick DR, Bielefeldt-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson RWS (1994) Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor infiltrating T-cells in malignant mesothelioma. Growth Factors 11:29PubMedCrossRefGoogle Scholar
  46. Fonagy A, Swiderski C, Dunn M, Freeman JW (1992) Antisense-mediated specific inhibition of p120 protein expression prevents G1 to S-phase transition. Cancer Res 52:5250PubMedGoogle Scholar
  47. Geiger T, Müller M, Monia BP, Fabbro D (1997) Antitumor activity of a c-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. Clin Cancer Res 3:1179–1185PubMedGoogle Scholar
  48. Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JA (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 53:1743PubMedGoogle Scholar
  49. Gottesman MM (1993) How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award lecture. Cancer Res 53:747PubMedGoogle Scholar
  50. Gray GD, Hernandez OM, Hebel D, Root M, Pow-Sang JM, Wickstrom E (1993) Antisense DNA inhibition of tumor growth induced by c-Ha-ras oncogene in nude mice. Cancer Res 53:577PubMedGoogle Scholar
  51. Gryaznov S, Skorski T, Cucco C, Nieborowska-Skorska M, Chiu CY, Lloyd D, Chen JK, Koziolkiewicz M, Calabretta B (1996) Oligonucleotide N3’-P5’ phosphoroamidates as antisense agents. Nucleic Acids Res 24:1508PubMedCrossRefGoogle Scholar
  52. Hansche GM, Wagner C, Burger JA, Dong W, Staehler G, Stoeck M (1995) Matrix protein synthesis by glomerular mesangial cells in culture: effects of transforming growth factor beta and platelet-derived growth factor on fibronectin and collagen type IV mRNA. J Cell Physiol 163:451CrossRefGoogle Scholar
  53. Hélène C, Toulmé JJ (1990) Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1049:99–125PubMedCrossRefGoogle Scholar
  54. Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA, Narayanan R (1993) Antisense inhibition of the p65 subunit of NF- KB blocks tumorigenicity and causes tumor regression. Proc Natl Acad Sci U S A 90:9901PubMedCrossRefGoogle Scholar
  55. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM (1994) Biologic and therapeutic significance of myb expression in human melanoma. Proc Natl Acad Sci U S A 91:4499PubMedCrossRefGoogle Scholar
  56. Hunter T (1991) Cooperation between oncogenes. Cell 64:249PubMedCrossRefGoogle Scholar
  57. Itoh H, Mukoyama M, Pratt RE, Dzau VJ (1992) Specific blockade of basic fibroblast growth factor gene expression in endothelial cells by antisense oligonucleotide. Biochem Biophys Res Commun 188:1205PubMedCrossRefGoogle Scholar
  58. Jaattelä M (1995) Overexpression of hsp70 confers tumorigenicity to mouse fibrosarcoma cells. Int J Cancer 60:689PubMedCrossRefGoogle Scholar
  59. Jachimczak P, Hessdorfer B, Fabel-Schulte K, Wismeth C, Brysch W, Schlingensiepen KH, Bauer A, Blesch A, Bogdahn U (1996) Transforming growth factor-betamediated autocrine growth regulation of gliomas as detected with phosphorothioate antisense oligonucleotides. Int J Cancer 65:332PubMedCrossRefGoogle Scholar
  60. Jaskulski D, deRiel JK, Mercer WE, Calabretta B, Baserga R (1988) Inhibition of cellular proliferation by antisense oligodeoxynucleotides to PCNa cyclin. Science 240:1544PubMedCrossRefGoogle Scholar
  61. Kasid U, Pfeifer A, Brennan T, Beckett M, Weichselbaum RR, Dristchilo A, Mark GE (1989) Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of human squamous carcinoma. Science 243:1354PubMedCrossRefGoogle Scholar
  62. Kaye SB (1993) P-glycoprotein (Pgp) and drug resistance-time for reappraisal? Br J Cancer 67:641PubMedCrossRefGoogle Scholar
  63. Kiehntopf M, Brach MA, Licht T, Petschauer S, Karawajew L, Kirschning C, Herrmann F (1994) Ribozyme-mediated cleavage of the MDR-1 transcript restores chemosensitivity in previously resistant cancer cells. Embo J 13:4645PubMedGoogle Scholar
  64. Kitajima I, Shinohara T, Biladovics J, Brown DA, Yu X, Nerenberg M (1992) Ablation of transplanted HTLV-1 Tax-transformed tumors in mice by antisense inhibition of NF-KB. Science 258:1792PubMedCrossRefGoogle Scholar
  65. Kobayashi H, Dorai T, Holland JF, Ohnuma T (1994) Reversal of drug sensitivity in multidrug-resistant tumor cells by a MDR1 (PGY1) ribozyme. Cancer Res 54:1271PubMedGoogle Scholar
  66. Kolch W, Heidecker G, Lloyd P, Rapp UR (1991) Raf-1 protein kinase is required for growth of induced NIH/3T3 cells. Nature 349:426PubMedCrossRefGoogle Scholar
  67. Kook YH, Adamski J, Zelen A, Ossowski L (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13:3983PubMedGoogle Scholar
  68. Laird AD, Brown PI, Fausto N (1994) Inhibition of tumor growth in liver epithelial cells transfected with a transforming growth factor-a antisense gene. Cancer Res 54:4224PubMedGoogle Scholar
  69. Lange W, Daskalakis M, Finke J, Dölken G (1994) Comparison of different ribozymes for efficient and specific cleavage of bcr/abl related mRNAs. FEBS Lett 338:175PubMedCrossRefGoogle Scholar
  70. Levi BZ, Ozato K (1988) Constitutive expression of c-fos antisense RNA blocks c-fos gene induction by interferon and by phorbol ester and reduces c-myc expression in F9 embryonal carcinoma cells. Genes Dev 2:554PubMedCrossRefGoogle Scholar
  71. Lewalle P, Martiat P (1993) Inhibition of p210 expression in chronic myeloid leukaemia: oligonucleotides and/or transduced antisense sequences. Leuk Lymphoma 11:139Google Scholar
  72. Long L, Rubin R, Baserga R, Brodt P (1995) Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 55:1006PubMedGoogle Scholar
  73. Magrath IT (1994) Prospects for the therapeutic use of antisense oligonucleotides in malignant lymphomas. Ann Oncol 5:S67CrossRefGoogle Scholar
  74. Martiat P, Lewalle P, Taj AS, Philippe M, Larondelle Y, Vaerman JL, Wildmann C, Goldman JM, Michaux JL (1993) Retrovirally transduced antisense sequences stably suppress p210 expression and inhibit the proliferation of bcr/abl-containing cell lines. Blood 81:502PubMedGoogle Scholar
  75. Melani C, Rivoltini L, Parmiani G, Calabretta B, Colombo MP (1991) Inhibition of proliferation of c-myb antisense oligodeoxynucleotides in colon adenocarcinoma cell lines that express c-myb. Cancer Res 51:2897PubMedGoogle Scholar
  76. Monia BP, Johnston JF, Geiger T, Müller M, Fabbro D (1996) Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against c-raf kinase. Nat Med 2:668PubMedCrossRefGoogle Scholar
  77. Monia BP, Samsor H, Johnston JF, Freier SM, Lesnik EA, Müller M, Geiger T, Altmann KH, Moser H, Fabbro D (1997) Sequence-specific antitumor activity of a phosphorothioate oligodeoxynucleotide targeted to human c-raf kinase supports an antisense mechanism of action in vivo. Proc Natl Acad Sci U S A 93:15481–15484CrossRefGoogle Scholar
  78. Moroni MC, Willingham MC, Beguinot L (1992) EGF receptor antisense RNA blocks expression of the epidermal growth factor receptor and suppresses the transforming phenotype of a human carcinoma cell line. J Biol Chem 267:2714PubMedGoogle Scholar
  79. Muszynski KW, Ruscetti FW, Heidecker G, Rapp U, Troppmair J, Gooya JM, Keller JR (1995) Raf-1 protein is required for growth factor-induced proliferation of hematopoietic cells. J Exp Med 181:2189PubMedCrossRefGoogle Scholar
  80. Narayanan R, Higgins KA, Perez JR, Coleman TA, Rosen CA (1993) Evidence for differential functions of the 50 and p65 subunits of NF-KB with a cell adhesion model. Mol Cell Biol 13:3802PubMedGoogle Scholar
  81. Nesterova M, Cho-Chung Y-S (1995) A single injection protein kinase A-directed antisense treatment to inhibit tumor growth. Nat Med 1:528PubMedCrossRefGoogle Scholar
  82. Neuenschwander S, Roberts CT, LeRoith D (1995) Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor-1 receptor antisense ribonucleic acid. Endocrinology 136:4298PubMedCrossRefGoogle Scholar
  83. Nishikura K, Kim U, Murray JM (1990) Differentiation of F9 cells is independent of cmyc expression. Oncogene 5:981PubMedGoogle Scholar
  84. Nowell PC, Hungerford DA (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1491Google Scholar
  85. O’Brien SG, Kirkland MA, Goldman JM (1994) Gene therapy — a future for cancer management. Eur J Cancer 30A:1160PubMedCrossRefGoogle Scholar
  86. Ouchida M, Ohno T, Fujimura Y, Rao VN, Reddy ES (1995) Loss of tumorigenicity of Ewing’s sarcoma cells expressing antisense RNA to EWS-fusion transcripts. Oncogene 11:1049PubMedGoogle Scholar
  87. Pastan I, Gottesman MM (1991) Multidrug resistance. Annu Rev Med 41:277CrossRefGoogle Scholar
  88. Paulus W, Baur I, Huettner C, Schmausser B, Roggendorf W, Schlingensiepen KH, Brysch W (1995) Effects of transforming growth factor-beta-1 on collagen synthesis, integrin expression, adhesion and invasion of glioma cells. J Neuropathol Exp Neurol 54:236PubMedCrossRefGoogle Scholar
  89. Perez JR, Higgins-Sochaski KA, Maltese JY, Narayanan R (1994) Regulation of adhesion and growth of fibrosarcoma cells by NF-x$ ReIA involves transforming growth factor ß. Mol Cell Biol 14:5326PubMedGoogle Scholar
  90. Perlaky L, Valdez BC, Busch RK, Larson RG, Jhiang SM, Zhang WW, Brattain M, Busch H (1992) Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct. Cancer Res 52:428Google Scholar
  91. Perlaky L, Saijo Y, Busch RK, Bennett CF, Mirabelli CK, Crooke ST, Busch H (1993) Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expression. Anticancer Drug Des 8:3PubMedGoogle Scholar
  92. Perletti GP, Smeraldi C, Porro D, Piccinini F (1994) Involvement of the alpha isoenzyme of protein kinase C in the growth inhibition induced by phorbol esters in MH1C1 hepatoma cells. Biochem Biophys Res Commun 205:1589PubMedCrossRefGoogle Scholar
  93. Pierga J-Y, Magdelenat H (1994) Applications of antisense oligonucleotides in oncology, Cell Mol Biol 40:237PubMedGoogle Scholar
  94. Pietrozkowski Z, Sell C, Lammers R, Ullrich A, Baserga R (1992) Roles of insulin-like growth factor-1 and the IGF-1 receptor in epidermal growth factor-stimulated growth of 3T3 cells. Mol Cell Biol 12:3883Google Scholar
  95. Quattrone A, Fibbi G, Anichini E, Zamperini A, Cappacioli S, del Rosso M (1995) Reversion of the invasive phenotype of transformed human fibroblasts by inhibition of urokinase receptor gene expression. Cancer Res 55:90PubMedGoogle Scholar
  96. Rabbitts TH (1994) Chromosomal translocations in human cancer. Nature 372:143PubMedCrossRefGoogle Scholar
  97. Ratajczak MZ, Hijiya N, Catani L, deRiel K, Luger SM, McGlave P, Gewirtz AM (1992) Acute-and chronic-phase chronic myelogenous leukemia colony-forming units are highly sensitive to the growth inhibitory effects of c-myb antisense oligodeoxynucleotides. Blood 79:1956PubMedGoogle Scholar
  98. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R (1994) Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type-1 insulin-like growth factor receptor. Cancer Res 54:4848PubMedGoogle Scholar
  99. Rivoltini L, Colombo MP, Supino R, Ballinari D, Tsuruo T, Parmiani G (1990) Modulation of multidrug resistance by verapamil or mdrl antisense oligodeoxynucleotides does not change the high susceptibility to lymphokine-activated killers in mdr-resistant human carcinoma (LoVo) line. Int J Cancer 46:727PubMedCrossRefGoogle Scholar
  100. Rowley JD (1982) Identification of the constant chromosome regions involved in human hematologic malignant diseases. Science 216:749PubMedCrossRefGoogle Scholar
  101. Rubenstein M, Mirochnik Y, Choi P, Guinan P (1996) Antisense oligonucleotide intralesional therapy for human PC-3 prostate tumors carried in athymic nude mice. J Surg Oncol 62:194–200PubMedCrossRefGoogle Scholar
  102. Saijo Y, Perlaky L, Valdez BC, Busch RK, Henning D, Zhang WW, Busch H (1993a) The effect of antisense p120 construct on p120 expression and cell proliferation in human breast cancer MCF-7 cells. Cancer Lett 68:95CrossRefGoogle Scholar
  103. Saijo Y, Perlaky L, Valdez BC, Wang H, Henning D, Busch H (1993b) Cellular pharmacology of p120 antisense oligodeoxynucleotide phosphorothioate ISIS 3466. Oncol Res 5:283Google Scholar
  104. Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, Takahashi T (1994) Inhibition of gastric cancer cell proliferation by antisense oligonucleotides targeting the messenger RNA encoding proliferating cell nuclear antigen. Br J Cancer 10:1060CrossRefGoogle Scholar
  105. Sakakura C, Hagiwara A, Tsujimoto H, Ozaki K, Sakakibara T, Oyama T, Ogaki M, Takahashi T (1995) The anti-proliferative effect of proliferating cell nuclear antigen-specific antisense oligonucleotides on human gastric cancer cell lines. Surg Today 25:184PubMedCrossRefGoogle Scholar
  106. Saleh M, Stacker SA, Wilks AF (1996) Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56:393PubMedGoogle Scholar
  107. Scanlon KJ, Ishida H, Kashani-Sabet M (1994) Ribozyme-mediated reversal of multidrug-resistant phenotype. Proc Natl Acad Sci U S A 91:11123PubMedCrossRefGoogle Scholar
  108. Schönthal A, Büscher M, Angel P, Rahmsdorf HJ, Ponta H, Hattori K, Chiu R, Karin M, Herrlich P (1989) The Fos and Jun/AP-1 proteins are involved in the downregulation of Fos transcription. Oncogene 4:629PubMedGoogle Scholar
  109. Schwab G, Chavany C, Duroux I, Goubin G, Lebeau J, Hélène C, Saison-Behmoaras T (1994) Antisense oligonucleotides absorbed to polyalkyl-cyanoacrylate nanoparticles specifically inhibit mutated Ha-ras-mediated cell proliferation and tumorigenicity in nude mice. Proc Natl Acad Sci 91:10460PubMedCrossRefGoogle Scholar
  110. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ (1994) Antisense-mediated reduction in insulin-like growth factor-1 receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 94:1235PubMedCrossRefGoogle Scholar
  111. Shi Y, Hutchinson HG, Gall DJ, Zalewski A (1993) Downregulation of c-myc expression by antisense oligonucleotides inhibits proliferation of human smooth muscle cells. Circulation 88:1190PubMedCrossRefGoogle Scholar
  112. Shustik C, Dalton W, Gros P (1995) P-glycoprotein-mediated multidrug resistance in tumor cells: biochemistry, clinical relevance and modulation. Mol Aspects Med 16:1PubMedCrossRefGoogle Scholar
  113. Simons M, Morgan KG, Parker C, Collins E, Rosenberg RD (1993) The protooncogene c-myb mediates an intracellular calcium rise during the late Gl phase of the cell cycle. J Biol Chem 286:627Google Scholar
  114. Skorski TT, Nieborowska-Skorska M, Barletta C, Malaguarnera L, Szczylik C, Chen ST, Lange B, Calabretta B (1993) Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antisense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92:194PubMedCrossRefGoogle Scholar
  115. Skorski T, Nieborowska-Skorska M, Nicolaides NC, Szcylik C, Iversen P, Iozzo RV, Zon G, Calabretta B (1994) Suppression of Philadelphia leukemia cell growth in mice by bcr-abl antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A 91:4504PubMedCrossRefGoogle Scholar
  116. Skorski T, Nieborowska-Skorska M, Szczylik C, Kanakaraj P, Perrotti D, Zon G, Gewirtz, A, Perussia B, Calabretta B (1995) c-RAF-1 serine/threonine kinase is required in BCR/ABL-dependent and normal hematopoiesis. Cancer Res 55: 2275PubMedGoogle Scholar
  117. Slamon DJ, Clark GM, Wong SG, Levin MJ, Ullrich A, McGuire WL (1987) Human breast carcinoma: correlation of relapse and survival with amplification of the Her2/neu oncogene. Science 235:177PubMedCrossRefGoogle Scholar
  118. Smeters TFC, Skorski T, van de Locht LTF, Wessels HM, Pennings AH, de Witte T, Calabretta B, Mensink EJ (1994) Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173. Leukemia 8:129Google Scholar
  119. Smeters TFC, van de Locht LTF, Pennings AHM, Wessels HMC, de Witte TM, Mensink EJB (1995) Phosphorothioate Bcr-abl antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels. Leukemia 9:118Google Scholar
  120. Sokoloski JA, Sartorelli AC, Rosen CA, Narayanan R (1993) Antisense oligonucleotides to the p65 subunit of NF-KB block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes. Blood 82:625PubMedGoogle Scholar
  121. Spearman M, Taylor WR, Greenberg AH, Wright JA (1994) Antisense oligodeoxynucleotide inhibition of TGF-/31 gene expression and alterations in the growth and malignant properties of mouse fibrosarcoma cells. Gene 149:25PubMedCrossRefGoogle Scholar
  122. Speir E, Epstein SE (1992) Inhibition of smooth muscle cell proliferation by an antisense oligodeoxynucleotide targeting the messenger RNA encoding proliferating cell nuclear antigene. Circulation 86:538PubMedCrossRefGoogle Scholar
  123. Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz A, Calabretta B (1991) Selective inhibition of leukemia cell proliferation by bcr-abl antisense oligonucleotides. Science 253:562PubMedCrossRefGoogle Scholar
  124. Thierry AR, Rahman A, Dritschilo A (1993) Overcoming multidrug resistance in human cells using free and liposomally encapsulated antisense oligonucleotides. Biochem Biophys Res Commun 190:952PubMedCrossRefGoogle Scholar
  125. Thomas M, Kosciolek B, Wang N, Rowley P (1994) Capping of bcr-abl antisense oligonucleotides enhances antiproliferative activity against chronic myeloid leukemia cell lines. Leuk Res 18:401PubMedCrossRefGoogle Scholar
  126. Vaerman JL, Lammineur C, Moureau P, Lewall P, Deldime M, Blumenfeld M, Martiat P (1995) BCR-ABL antisense oligodeoxyribonucleotides suppress the growth of leukemic and normal hematopoietic cells by a sequence-specific but nonantisense mechanism. Blood 10:3891Google Scholar
  127. van Kalken, CK, Pinedo HM, Giaccone G (1991) Multidrug resistance from the clinical point of view. Eur J Cancer 27:1481PubMedCrossRefGoogle Scholar
  128. Venturelli D, Travali S, Calabretta B (1990) Inhibition of T-cell proliferation by a MYB antisense oligomer is accompanied by selective down-regulation of DNA polymerase a expression. Proc Natl Acad Sci U S A 87:5963PubMedCrossRefGoogle Scholar
  129. Watson PH, Pon RT, Shiu RPC (1991) Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996PubMedGoogle Scholar
  130. Weinberg RA (1994) Oncogenes and tumor suppressor genes. CA Cancer J Clin 44: 160PubMedCrossRefGoogle Scholar
  131. Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E (1988) Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by an antisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A 85:1028PubMedCrossRefGoogle Scholar
  132. Wilhelm O, Schmitt M, Höhl S, Senekowitsch R, Graeff H (1995) Antisense inhibition of urokinase reduces spread of human ovarian cancer in mice. Clin Exp Metastasis 13:296PubMedCrossRefGoogle Scholar
  133. Witty JP, McDonnell S, Newell KJ, Cannon P, Navre M, Tressler RJ, Matrisian L (1994) Modulation of matrilysin levels in colon carcinoma cell lines affects tumorigenicity in vivo. Cancer Res 54:4805PubMedGoogle Scholar
  134. Ye X, Wu M (1992) Retrovirus mediated transfer of antisense human c-myc gene into human esophageal cancer cells suppressed cell proliferation and malignancy. Sci China B 35:76PubMedGoogle Scholar
  135. Yokozaki H, Budillon A, Tortora G, Meissner S, Beaucage SL, Miki K, Cho-Chung YS (1993) An antisense oligodeoxynucleotide that depletes RIa subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res 53:868PubMedGoogle Scholar
  136. Zhou P, Jiang W, Zhang YJ, Kahn SM, Schieren I, Santella RM, Weinstein IB (1995) Antisense to cyclin D1 inhibits growth and reverses the transformed phenotype of human esophageal cancer cells. Oncogene 11:571PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1998

Authors and Affiliations

  • D. Fabbro
  • M. Müller
  • T. Geiger

There are no affiliations available

Personalised recommendations